

In the Specification

Please replace the paragraph at page 17, lines 1 through 10 with the following paragraph:

AA1
filed November 16, 1998, and in U.S.S.N. PCT/US98/26058, "Restin and Methods of Use Thereof," by Vikas P. Sukhatme, filed December 8, 1998, and in its U.S. designation U.S.S.N. 09/589,774 and PCT/US98/25892, "Methods of Producing Anti-Angiogenic Proteins," by Vikas P. Sukhatme, filed December 7, 1998, and in its U.S. designation U.S.S.N. 09/589,483 the entire teachings of all of which are herein incorporated by reference. Such methods are also included in Dhanabal *et al.* (1999) ("Endostatin Induces Endothelial Cell Apoptosis," *J. Biol. Chem.*, 274:11721-6), and in Dhanabal *et al.* (1999) ("Cloning, Expression and *in vitro* Activity of Human Endostatin," *Bioch. Biophys. Res. Commun.* 258:345-52). Evaluating the ED₅₀ of a mutant in one of the assays described herein is a useful method of comparing activities.

Please replace the paragraph at page 15, lines 1 through 8 with the following paragraph:

AA2
Exemplary methods of producing anti-angiogenic proteins in general, and EM 1 in particular, are provided in the Examples below, and also in PCT/US98/25892, "Methods of Producing Anti-Angiogenic Proteins," by Vikas P. Sukhatme, filed December 7, 1998, and its U.S. designation U.S.S.N. 09/589,483, the entire teachings of which are herein incorporated by reference. The EM 1 protein may also be expressed as a product of transgenic animals, *e.g.*, as a component of the milk of transgenic cows, goats, sheep or pigs, or as a product of a transgenic plant, *e.g.*, combined or linked with starch molecules in maize.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).